JP7642608B2 - ハンタウイルス抗原性組成物 - Google Patents

ハンタウイルス抗原性組成物 Download PDF

Info

Publication number
JP7642608B2
JP7642608B2 JP2022506337A JP2022506337A JP7642608B2 JP 7642608 B2 JP7642608 B2 JP 7642608B2 JP 2022506337 A JP2022506337 A JP 2022506337A JP 2022506337 A JP2022506337 A JP 2022506337A JP 7642608 B2 JP7642608 B2 JP 7642608B2
Authority
JP
Japan
Prior art keywords
vector
nucleic acid
acid sequence
seq
hantavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022506337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547786A5 (https=
JP2022547786A (ja
Inventor
ヒューソン，ロジャー
ドウォール，スチュアート
ケネディー，エマ
キャロル，マイルズ
Original Assignee
セクレタリー オブ ステイト フォー ヘルス アンド ソーシャル ケア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セクレタリー オブ ステイト フォー ヘルス アンド ソーシャル ケア filed Critical セクレタリー オブ ステイト フォー ヘルス アンド ソーシャル ケア
Publication of JP2022547786A publication Critical patent/JP2022547786A/ja
Publication of JP2022547786A5 publication Critical patent/JP2022547786A5/ja
Priority to JP2025029451A priority Critical patent/JP2025084850A/ja
Application granted granted Critical
Publication of JP7642608B2 publication Critical patent/JP7642608B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12111—Hantavirus, e.g. Hantaan virus
    • C12N2760/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12111—Hantavirus, e.g. Hantaan virus
    • C12N2760/12151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12111—Hantavirus, e.g. Hantaan virus
    • C12N2760/12161—Methods of inactivation or attenuation
    • C12N2760/12162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
JP2022506337A 2019-07-29 2020-07-29 ハンタウイルス抗原性組成物 Active JP7642608B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025029451A JP2025084850A (ja) 2019-07-29 2025-02-26 ハンタウイルス抗原性組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1910804.2A GB201910804D0 (en) 2019-07-29 2019-07-29 Hantavirus antigenic Composition
GB1910804.2 2019-07-29
PCT/GB2020/051813 WO2021019235A2 (en) 2019-07-29 2020-07-29 Hantavirus antigenic composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025029451A Division JP2025084850A (ja) 2019-07-29 2025-02-26 ハンタウイルス抗原性組成物

Publications (3)

Publication Number Publication Date
JP2022547786A JP2022547786A (ja) 2022-11-16
JP2022547786A5 JP2022547786A5 (https=) 2023-07-11
JP7642608B2 true JP7642608B2 (ja) 2025-03-10

Family

ID=67990345

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022506337A Active JP7642608B2 (ja) 2019-07-29 2020-07-29 ハンタウイルス抗原性組成物
JP2025029451A Pending JP2025084850A (ja) 2019-07-29 2025-02-26 ハンタウイルス抗原性組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025029451A Pending JP2025084850A (ja) 2019-07-29 2025-02-26 ハンタウイルス抗原性組成物

Country Status (7)

Country Link
US (1) US20220275346A1 (https=)
EP (1) EP4003413A2 (https=)
JP (2) JP7642608B2 (https=)
KR (1) KR20220038755A (https=)
CN (2) CN114269939B (https=)
GB (1) GB201910804D0 (https=)
WO (1) WO2021019235A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113234129B (zh) * 2021-05-08 2023-02-07 中国人民解放军空军军医大学 Hla-e限制性htnv结构蛋白特异性cd8+t细胞表位肽及其聚合物和应用
US20250127870A1 (en) * 2021-09-16 2025-04-24 Board Of Regents, The University Of Texas System mRNA Vaccines Against Hantavirus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020114818A1 (en) 1999-01-29 2002-08-22 Schmaljohn Connie S. DNA Vaccines against hantavirus infections
WO2006022461A1 (en) 2004-08-27 2006-03-02 Nexgen Biotechnologies, Inc. Diagnosis kits for hemorrhagic fever with renal syndrome comprising nucleocapsid protein of hanta virus expressed in transformed plant
JP2008503720A (ja) 2004-06-18 2008-02-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ハンタウイルス感染の診断のための方法および試薬

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4473497A (en) * 1996-10-04 1998-04-24 Cheil Jedang Corporation Nucleocapsid gene of seoul virus r22, recombinant plasmid, transformed e. coli and diagnostic agent and vaccine for haemorrhagic fever with renal syndrome
US11602557B2 (en) * 2017-08-22 2023-03-14 Cure Vac SE Bunyavirales vaccine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020114818A1 (en) 1999-01-29 2002-08-22 Schmaljohn Connie S. DNA Vaccines against hantavirus infections
JP2008503720A (ja) 2004-06-18 2008-02-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ハンタウイルス感染の診断のための方法および試薬
WO2006022461A1 (en) 2004-08-27 2006-03-02 Nexgen Biotechnologies, Inc. Diagnosis kits for hemorrhagic fever with renal syndrome comprising nucleocapsid protein of hanta virus expressed in transformed plant

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Human Vaccines & Immunotherapeutics，2012年，Vol.8, No.2，pp.208-215
International Journal of Molecular Medicine，2013年，Vol.32，pp.709-716
Journal of Clinical Microbiology，1998年，Vol.36, No.9，pp.2514-2521
Journal of Virology，1990年，Vol.64, No.7，pp.3162-3170
Journal of Virology，1995年，Vol.69, No.10，pp.6417-6423
Journal of Virology，2009年，Vol.83, No.14，pp.7285-7295
Vaccine，2001年，Vol.19，pp.3820-3829
Virology，1999年，Vol.263，pp.209-219
Virus Research，2002年，Vol.84，pp.67-77

Also Published As

Publication number Publication date
CN114269939B (zh) 2025-08-05
JP2025084850A (ja) 2025-06-03
WO2021019235A3 (en) 2021-04-29
CN119144656A (zh) 2024-12-17
GB201910804D0 (en) 2019-09-11
EP4003413A2 (en) 2022-06-01
WO2021019235A2 (en) 2021-02-04
JP2022547786A (ja) 2022-11-16
CN114269939A (zh) 2022-04-01
US20220275346A1 (en) 2022-09-01
KR20220038755A (ko) 2022-03-29

Similar Documents

Publication Publication Date Title
EP2961846B1 (en) Crimean-congo haemorrhagic fever virus antigenic composition
CN105980570B (zh) Cmv疫苗
CN107921117B (zh) Hpv疫苗
CN113666990B (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
RU2609645C2 (ru) Экспрессионные системы
CN115529817A (zh) 疫苗及其诱导针对sars-cov2的免疫应答的用途
WO2020063370A2 (zh) 免疫组合物及其制备方法与应用
IL298333A (en) A viral assembly vector for a vaccine against the corona virus cell
JP2025084850A (ja) ハンタウイルス抗原性組成物
US20240123053A1 (en) Coronavirus vaccine through nasal immunization
CN116059336A (zh) 针对rsv的疫苗
CN111741766A (zh) 用于诱导针对乙型肝炎病毒(hbv)的免疫应答的方法和组合物
CN109923125B (zh) 免疫原性组合物
US20250026793A1 (en) Chimeric betacoronavirus spike polypeptides
WO2023031869A1 (en) Bovine ephemeral fever and lumpy skin disease antigenic constructs
JP2024512103A (ja) ワクチンプラットフォームとしての高弱毒化複製可能組換えポックスウイルスおよびその利用方法
WO2025044919A2 (en) New dev vectors
CA2962100A1 (en) Virus-based expression vectors and uses thereof
JP2023529124A (ja) コロナウイルスワクチンコンストラクトおよびこれを作製し使用する方法
CN110382518B (zh) 用于血清型a型口蹄疫病毒的嵌合疫苗
WO2019145739A1 (en) Lassa virus antigenic composition
US20260007734A1 (en) Immunogenic compositions for the prevention of influenza a
RU2853400C1 (ru) Иммунобиологическое средство для индукции специфического иммунного ответа против поксвирусов и его применение
GB2624391A (en) Recombinant LSDV vectored bovine coronavirus antigen constructs
CN111712575B (zh) 表达外源猫副粘病毒基因的重组病毒载体系统及由其制备的疫苗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250226

R150 Certificate of patent or registration of utility model

Ref document number: 7642608

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150